Therapeutic Solutions International to Provide Patients Access to StemVacs Cancer Immunotherapy through Right to Try Law
May 31 2018 - 9:00AM
InvestorsHub NewsWire
Therapeutic Solutions
International to Provide Patients Access to StemVacs Cancer
Immunotherapy through Newly Passed Right to Try
Law
Oceanside, CA
-- May
31, 2018
--
InvestorsHub NewsWire -- Therapeutics
Solutions International, Inc., (OTC
Markets:
TSOI) announced
today their
plans
to provide access to its
clinical stage cancer immunotherapy product StemVacs under
the Right To Try law
signed by President Trump on May 30th, 2018.
At the signing
President Trump said the following "With
the Right to Try law I'm signing today, patients with
life-threatening illnesses will finally have access to experimental
treatments that could improve or even cure their
conditions.
These
are experimental treatments and products that have shown great
promise, and we weren't able to use them before.
Now we
can use them.
And
oftentimes they're going to be very successful.
It's
an incredible thing."
"Having successfully
completed a Phase 1 Clinical trial in Mexico using our StemVacs
cancer platform with ten
patients, we
are
reviewing our data to determine its applicability under this new
law. In the previous study no patients had any reportable adverse
events associated with the administration of
StemVacs" said Timothy Dixon,
President, and CEO of Therapeutic Solutions International.
"We
recently announced the licensing of our StemVacs platform to Pan
American Cancer Treatment Center in Tijuana Mexico, and we are
currently offering cancer treatment in stages 1-4 in both prostate
and breast cancer, and we intend to continue offering the platform
at Pan Am" added Mr. Dixon.
"This
bill
signed
into law by President Trump would
allow those with potentially terminal diseases to try experimental
treatments and bypass the U.S. FDA.
As a physician that has watched many promising drugs take up to 15
years for approval, it's tragic, and this is far too long for dying
patients to wait.
The
StemVacs platform allows TSOI to build custom vaccines for each
patient across a wide variety of cancers including prostate,
breast, lung, liver, and kidney using
dendritic cells from patients, which are activated by our
proprietary process enabling the dendritic cells to produce
"natural cytokines", which kill cancer cells." said
Dr. James
Veltmeyer, Republican Congressional Candidate and Scientific
Advisory Board Member of TSOI.
About Therapeutic Solutions International,
Inc.
Therapeutic Solutions
International is focused on immune modulation for the treatment of
several specific diseases. Immune modulation refers to the ability
to upregulate (make more active) or
downregulate (make less active) one's immune system. The Company's
corporate website is www.therapeuticsolutionsint.com
and
e-commerce at www.youcanordernow.com.
Safe Harbor
Statement
This release contains
forward-looking statements that are based upon current expectations
or beliefs, as well as a number of assumptions about future events.
Although we believe that the expectations reflected in the
forward-looking statements and the assumptions upon which they are
based are reasonable, we can give no assurance that such
expectations and assumptions will prove to have been correct.
Forward-looking statements are generally identifiable by the use of
words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements
are subject to numerous risk factors as set forth in our SEC
filings. To the extent that statements in this press release are
not strictly historical, including statements as to product launch
timing, revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
collaboration agreements, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The forward-looking statements contained in this release
are subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements
made.
CONTACT
INFORMATION
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Sep 2023 to Sep 2024